Psilocybine services in Oregon: a call for awareness among clinical toxicologists.
Clinical toxicology (Philadelphia, Pa.) March 1, 2023 DOI: 10.1080/15563650.2023.2182664
Summary
Oregon's groundbreaking psychedelic program allows supervised psilocybine sessions in licensed facilities, marking a new era in mental health treatment. Medical experts highlight key public health considerations, including how trained facilitators can recognize adverse events and manage emergencies. While supporting safe access, toxicology specialists emphasize the need for careful screening and monitoring to ensure positive outcomes for participants.
Abstract
In 2023, Oregon enacted laws regulating the manufacture and use of psilocybine products in licensed facilities for supervised sessions with trained facilitators. This commentary summarizes the final rules for psilocybine services in Oregon, and provides perspectives from a clinical toxicologist on some of the issues that may arise. These include the scope of practice for non-clinical facilitators, prevention and management of adverse drug reactions, and toxicological uncertainties with regards to dose considerations for people with mental health and other medical conditions. This commentary addresses some common misperceptions relating to the program, and provides perspective on some of the challenges that clinical toxicologists may encounter as legislative reform initiatives for psilocybine move forward throughout the United States.